Medtech Developer Surges on Triple-Digit EBITDA Growth
Scaling a specialized hospital consumable requires moving beyond single-department trials into broader facility-wide adoption. When infection-control vendors successfully expand across multiple care units and hospital networks, recurring high-margin product sales establish a predictable foundation for sustainable, debt-free cash flow. Covalon Technologies Ltd. (TSX-Venture: COV) (OTCQX: CVALF) advanced after reporting fiscal 2026 third-quarter results for the period ended June 30, 2026.Revenue rose 20% year-over-year to $10.0M, driven by a 51% surge in its US Vascular Access and Surgical ...